Skip to main content

What the FDA labels say about taking them together

Erlotinib and ritonavir

Erlotinib's FDA label of June 10, 2024 names ritonavir in its drug interactions section; the ritonavir label PlainMeds reads does not name erlotinib. The erlotinib label: “Avoid co-administering erlotinib with strong CYP3A4 inhibitors or a combined CYP3A4 and CYP1A2 inhibitor (e.g., ciprofloxacin).”

Check it at the source: the erlotinib FDA label on DailyMed (effective June 10, 2024, Alembic Pharmaceuticals Limited); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).

What does the erlotinib label say about ritonavir?

Erlotinib label, drug interactions

Avoid co-administering erlotinib with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) or a combined CYP3A4 and CYP1A2 inhibitor (e.g., ciprofloxacin).

Source: FDA drug label (ERLOTINIB HYDROCHLORIDE), Alembic Pharmaceuticals Limited, effective June 10, 2024 (SPL set ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b), via openFDA; the full label on DailyMed

What does the ritonavir label say about erlotinib?

Ritonavir's label (effective July 23, 2026) does not name erlotinib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

10Erlotinib generic labelers
7Ritonavir generic labelers
ErlotinibRitonavir
Labeled forLung cancerHIV
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.607 per tablet 100 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?